Literature DB >> 34848579

Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era.

Suzanne M McCluskey1,2,3, Toby Pepperrell4, Andrew Hill5, Willem D F Venter6, Ravindra K Gupta7,8, Mark J Siedner1,2,3,7.   

Abstract

Dolutegravir (DTG) is now a component of preferred first-line antiretroviral therapy (ART) worldwide. ADVANCE and NAMSAL were two landmark clinical trials conducted exclusively in sub-Saharan Africa, which studied the effectiveness of DTG-based first-line regimens for ART-naive individuals. In this review, we examine the data from these studies to consider the contributions of adherence and HIV drug resistance to treatment failure on DTG-based ART, as compared with efavirenz (EFV)-based ART, which has a lower genetic barrier to resistance. We also discuss the implications of virologic failure on DTG and consolidate currently available data to conclude with recommendations for virologic monitoring on DTG-based ART.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34848579      PMCID： PMC8647784          DOI： 10.1097/QAD.0000000000003082

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  39 in total

Review 1.  Single-pill combination regimens for treatment of HIV-1 infection.

Authors:  Monica Gandhi; Rajesh T Gandhi
Journal:  N Engl J Med       Date:  2014-07-17       Impact factor: 91.245

2.  Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.

Authors:  Kassem Bourgi; Peter F Rebeiro; Megan Turner; Jessica L Castilho; Todd Hulgan; Stephen P Raffanti; John R Koethe; Timothy R Sterling
Journal:  Clin Infect Dis       Date:  2020-03-17       Impact factor: 9.079

3.  Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.

Authors:  Willem D F Venter; Michelle Moorhouse; Simiso Sokhela; Lee Fairlie; Nkuli Mashabane; Masebole Masenya; Celicia Serenata; Godspower Akpomiemie; Ambar Qavi; Nomathemba Chandiwana; Shane Norris; Matthew Chersich; Polly Clayden; Elaine Abrams; Natasha Arulappan; Alinda Vos; Kaitlyn McCann; Bryony Simmons; Andrew Hill
Journal:  N Engl J Med       Date:  2019-07-24       Impact factor: 91.245

4.  Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

Authors:  Sharon L Walmsley; Antonio Antela; Nathan Clumeck; Dan Duiculescu; Andrea Eberhard; Felix Gutiérrez; Laurent Hocqueloux; Franco Maggiolo; Uriel Sandkovsky; Catherine Granier; Keith Pappa; Brian Wynne; Sherene Min; Garrett Nichols
Journal:  N Engl J Med       Date:  2013-11-07       Impact factor: 91.245

5.  Human immunodeficiency virus reverse transcriptase and protease sequence database.

Authors:  Soo-Yon Rhee; Matthew J Gonzales; Rami Kantor; Bradley J Betts; Jaideep Ravela; Robert W Shafer
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

6.  Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.

Authors:  Bonaventura Clotet; Judith Feinberg; Jan van Lunzen; Marie-Aude Khuong-Josses; Andrea Antinori; Irina Dumitru; Vadim Pokrovskiy; Jan Fehr; Roberto Ortiz; Michael Saag; Julia Harris; Clare Brennan; Tamio Fujiwara; Sherene Min
Journal:  Lancet       Date:  2014-04-01       Impact factor: 79.321

7.  High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy.

Authors:  Ravindra K Gupta; Ruth L Goodall; Michael Ranopa; Cissy Kityo; Paula Munderi; Fred Lyagoba; Lincoln Mugarura; Charles F Gilks; Pontiano Kaleebu; Deenan Pillay
Journal:  Clin Infect Dis       Date:  2013-12-18       Impact factor: 9.079

8.  Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase.

Authors:  Mark J Siedner; Michelle A Moorhouse; Bryony Simmons; Tulio de Oliveira; Richard Lessells; Jennifer Giandhari; Stephen A Kemp; Benjamin Chimukangara; Godspower Akpomiemie; Celicia M Serenata; Willem D F Venter; Andrew Hill; Ravindra K Gupta
Journal:  Nat Commun       Date:  2020-12-01       Impact factor: 14.919

9.  Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.

Authors:  John Gregson; Pontiano Kaleebu; Vincent C Marconi; Cloete van Vuuren; Nicaise Ndembi; Raph L Hamers; Phyllis Kanki; Christopher J Hoffmann; Shahin Lockman; Deenan Pillay; Tulio de Oliveira; Nathan Clumeck; Gillian Hunt; Bernhard Kerschberger; Robert W Shafer; Chunfu Yang; Elliot Raizes; Rami Kantor; Ravindra K Gupta
Journal:  Lancet Infect Dis       Date:  2016-12-01       Impact factor: 25.071

10.  HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis.

Authors:  Ravindra K Gupta; John Gregson; Neil Parkin; Hiwot Haile-Selassie; Amilcar Tanuri; Liliana Andrade Forero; Pontiano Kaleebu; Christine Watera; Avelin Aghokeng; Nicholus Mutenda; Janet Dzangare; San Hone; Zaw Zaw Hang; Judith Garcia; Zully Garcia; Paola Marchorro; Enrique Beteta; Amalia Giron; Raph Hamers; Seth Inzaule; Lisa M Frenkel; Michael H Chung; Tulio de Oliveira; Deenan Pillay; Kogie Naidoo; Ayesha Kharsany; Ruthiran Kugathasan; Teresa Cutino; Gillian Hunt; Santiago Avila Rios; Meg Doherty; Michael R Jordan; Silvia Bertagnolio
Journal:  Lancet Infect Dis       Date:  2017-12-05       Impact factor: 25.071
View more
  3 in total

1.  Comparative Clinical Outcomes With Scale-up of Dolutegravir as First-Line Antiretroviral Therapy in Ukraine.

Authors:  Kostyantyn Dumchev; Tetiana Kiriazova; Serhiy Riabokon; Alyona Shost; Canada Parrish; Anna Shapoval; Myroslava Germanovych; Jeremy Penner; Jason Beste; Nancy Puttkammer
Journal:  J Acquir Immune Defic Syndr       Date:  2022-10-01       Impact factor: 3.771

2.  Adherence to Antiretroviral Therapy and Associated Factors Among People Living With HIV Following the Introduction of Dolutegravir Based Regimens in Dar es Salaam, Tanzania.

Authors:  Mary Spicar Kilapilo; Raphael Zozimus Sangeda; George M Bwire; Godfrey Leonard Sambayi; Idda Hubert Mosha; Japhet Killewo
Journal:  J Int Assoc Provid AIDS Care       Date:  2022 Jan-Dec

3.  High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.

Authors:  Paul E Sax; Kristen Andreatta; Jean-Michel Molina; Eric S Daar; Debbie Hagins; Rima Acosta; Michelle L D'Antoni; Silvia Chang; Ross Martin; Hui Liu; Christiana Blair; Ian McNicholl; Joel Gallant; Sean E Collins; Hal Martin; Kirsten L White
Journal:  AIDS       Date:  2022-04-23       Impact factor: 4.632
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.